News & Updates

Patients with childhood-onset chronic rheumatic disease (CRD) do not perform as well as their peers on grade 12 standardized testing, independent of sociodemographic and mental health comorbidities, reports a population-based retrospective cohort study.

In the treatment of patients with psoriatic arthritis, the use of the selective TYK2 inhibitor deucravacitinib appears to be effective and well tolerated, leading to greater improvements in American College of Rheumatology (ACR) domains, enthesitis endpoints, and multiple patient-reported, psoriasis-related outcomes relative to placebo, as shown in the results of a phase II trial.

Use of tumour necrosis factor inhibitor (TNFi) does not appear to contribute to incident hypertension in individuals with ankylosing spondylitis (AS), reports a study.

Harnessing electronic (eHealth) and mobile health (mHealth) interventions appears to be an efficient way of supplementing the management of juvenile idiopathic arthritis (JIA), as shown by the results of a systematic review and meta-analysis.

Gout patients have about sixfold greater odds of experiencing a flare in the first few months after COVID-19 vaccination, but colchicine appears to keep these gout attacks at bay, as shown in a study from China.

The novel topical nonsteroidal anti-inflammatory drug (NSAID) S-flurbiprofen plaster provides relief from pain that appears similar to that achieved with diclofenac gel in patients with knee osteoarthritis, in addition to being well tolerated, according to data from an open-label, noninferiority phase III study.

Deucravacitinib, a selective TYK2 inhibitor, is well tolerated and appears to produce marked improvements in American College of Rheumatology 20 (ACR20) and other endpoints in the treatment of patients with psoriatic arthritis (PsA), according to the results of a phase II study.